Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xtant Medical Holdings Inc (XTNT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/14/2025: XTNT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $1.75
1 Year Target Price $1.75
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 25.7% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 04/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 87.63M USD | Price to earnings Ratio - | 1Y Target Price 1.75 |
Price to earnings Ratio - | 1Y Target Price 1.75 | ||
Volume (30-day avg) 2 | Beta -0.17 | 52 Weeks Range 0.33 - 0.83 | Updated Date 06/30/2025 |
52 Weeks Range 0.33 - 0.83 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.09 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.81% | Operating Margin (TTM) 3.23% |
Management Effectiveness
Return on Assets (TTM) -4.97% | Return on Equity (TTM) -26.19% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 116897275 | Price to Sales(TTM) 0.72 |
Enterprise Value 116897275 | Price to Sales(TTM) 0.72 | ||
Enterprise Value to Revenue 0.96 | Enterprise Value to EBITDA 46.01 | Shares Outstanding 139323008 | Shares Floating 36844013 |
Shares Outstanding 139323008 | Shares Floating 36844013 | ||
Percent Insiders 14.69 | Percent Institutions 57.58 |
Analyst Ratings
Rating 2 | Target Price 1.75 | Buy - | Strong Buy 2 |
Buy - | Strong Buy 2 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xtant Medical Holdings Inc
Company Overview
History and Background
Xtant Medical Holdings Inc. (formerly Bacterin International Holdings) was founded in 2006. It focuses on developing, manufacturing, and marketing orthopedic and spine products. The company has evolved through acquisitions and internal development to offer a comprehensive portfolio of biologics and spinal implants.
Core Business Areas
- Spinal Implants: Development and sale of spinal implants for fusion procedures, addressing various spinal pathologies.
- Biologics: Processing and marketing of allograft tissue products for bone grafting and tissue regeneration.
- Surgical Instruments: Offering a range of surgical instruments designed for use with their implants and biologics.
Leadership and Structure
Sean Browne serves as the CEO of Xtant Medical. The organizational structure includes departments for research and development, manufacturing, sales and marketing, and finance.
Top Products and Market Share
Key Offerings
- OsteoSelect DBM Putty: Demineralized Bone Matrix (DBM) putty used in spinal fusion. Market share data is not readily available. Competitors include Medtronic, Stryker, and Zimmer Biomet.
- 3Demu2122 Porous PEEK Scaffolds: Porous PEEK Interbody Fusion Device. Market share data is not readily available. Competitors include Globus Medical, NuVasive, and SeaSpine.
- Xtant Cortical Fiber: Allograft material for bone grafting. Market share data is not readily available. Competitors include MTF Biologics, AlloSource, and RTI Surgical.
Market Dynamics
Industry Overview
The orthopedic and spine market is characterized by technological advancements, increasing demand for minimally invasive procedures, and an aging population. It is a competitive market with large established players and emerging smaller companies.
Positioning
Xtant Medical is positioned as a provider of biologics and spinal implant solutions, aiming to compete with larger players through innovation and specialized product offerings.
Total Addressable Market (TAM)
The global spine market is estimated to be in the billions of dollars. Xtant Medical holds a small portion of this market and is positioning itself to take larger share.
Upturn SWOT Analysis
Strengths
- Comprehensive product portfolio
- Focus on biologics and spinal implants
- Innovative technologies
- Distribution network
Weaknesses
- Limited market share compared to larger competitors
- Financial constraints
- Dependence on third-party manufacturers for certain products
- History of operating losses
Opportunities
- Expanding product offerings
- Acquiring complementary technologies
- Increasing adoption of minimally invasive procedures
- Partnerships with other medical device companies
Threats
- Intense competition
- Regulatory changes
- Product liability risks
- Economic downturns
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- ZBH
- NUVA
- GMED
Competitive Landscape
Xtant Medical faces stiff competition from larger, well-established companies. Its competitive advantage lies in its focused product portfolio and innovative technologies. Disadvantages include limited resources and market reach compared to larger players.
Growth Trajectory and Initiatives
Historical Growth: Growth trends can be identified by examining historical revenue and earnings data.
Future Projections: Future projections are not available as I have no access to live, up-to-date financial data and analyst data.
Recent Initiatives: Recent initiatives are identified in company press releases and investor presentations. These may include product launches, acquisitions, or strategic partnerships.
Summary
Xtant Medical is a smaller player in a highly competitive orthopedic and spine market. The company's focus on biologics and spinal implants provides a niche, but it faces challenges related to financial resources and competition from larger firms. Strategic initiatives and acquisitions could improve its market position and growth prospects, however, continued operating losses and external threats need to be addressed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Press Releases, Industry Reports, Investor Presentations
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Market share data is approximate and may vary based on the source. Financial data is based on publicly available information and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xtant Medical Holdings Inc
Exchange NYSE MKT | Headquaters Belgrade, MT, United States | ||
IPO Launch date 2015-10-19 | President, CEO & Director Mr. Sean E. Browne | ||
Sector Healthcare | Industry Medical Devices | Full time employees 217 | Website https://xtantmedical.com |
Full time employees 217 | Website https://xtantmedical.com | ||
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, which can be compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, an aseptically processed and viable bone allograft; and nanOss products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier. It also provides sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and plastic/reconstructive applications. In addition, the company offers cervical products comprising Spider cervical plating, Streamline OCT, and CervAlign systems; thoracolumbar products consisting of Axle-X interspinous fusion, Streamline MIS spinal fixation, Streamline TL spinal fixation, and HPS 2.0 hybrid performance systems; and Silex sacroiliac joint fusion systems. Further, it provides interbody products comprising Calix for cervical and thoracolumbar applications, Irix-C Cervical and Irix-A lumbar integrated dusion systems, and Fortilink implants; and interlaminar stabilization products, such as Coflex device for lumbar spinal stenosis; and CoFix implants for back and disc pain. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.